The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA Detection in Muscle-invasive Bladder Cancer [0.03%]
肌层浸润性膀胱癌中肾脏、肝脏功能及免疫状态对循环肿瘤DNA检测的影响
Deema Radif,Sia Viborg Lindskrog,Iver Nordentoft et al.
Deema Radif et al.
Background and objective: The kidneys and liver play key roles in the metabolism of circulating molecules, including nucleic acids. To advance the clinical utility of circulating tumor DNA (ctDNA), it is essential to exam...
Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear-cell Renal Cell Carcinoma: The Multicentre, Single-arm, Phase 2 RENALUT Trial [0.03%]
[177Lu]Lu-PSMA-617治疗转移性透明细胞肾细胞癌患者的疗效：多中心、单臂、Ⅱ期RENALUT试验
Emmanuel Seront,Mehdi Bsilat,Karolien Goffin et al.
Emmanuel Seront et al.
Background and objective: Angiogenesis-targeting tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) are standard treatments for metastatic clear-cell renal cell carcinoma (ccRCC). However, therapeut...
Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer [0.03%]
顺铂适合型肌侵袭性膀胱癌的新辅助化疗的再评价
Javier Molina-Cerrillo,James Catto,Ashish M Kamat et al.
Javier Molina-Cerrillo et al.
Background and objective: Management of muscle-invasive bladder cancer (MIBC) is evolving rapidly due to advances in systemic therapies and molecular understanding. Neoadjuvant cisplatin-based chemotherapy remains the cor...
Prognostic Implications of Very High Decipher Scores in Prostate Cancer: Towards a Refined Genomic Risk Classification [0.03%]
前列腺癌的极高Decipher评分预后意义：迈向精确的基因组风险分类
Rohan Sharma,Marcio C Moschovas,Seetharam K R Bhatt et al.
Rohan Sharma et al.
Background and objective: The 22-gene Decipher genomic classifier (DGC) is validated for risk stratification in prostate cancer. Our aim was to evaluate the association of a novel very high-risk (VHR) group (DGC score >0....
Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis [0.03%]
转移性激素敏感型前列腺癌的治疗路径：来自PIONEER+大数据分析的结论
Rossella Nicoletti,Alex Qinyang Liu,Susan Evans-Axelsson et al.
Rossella Nicoletti et al.
Background and objective: The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) is evolving rapidly. Real-world data (RWD) are essential to understand actual treatment use and outcomes. This stu...
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis [0.03%]
卡巴他赛对比阿比特龙或恩杂鲁胺治疗多西他赛治疗后预后不良的转移性去势抵抗性前列腺癌患者：一项Ⅱ期研究联合循环肿瘤DNA分析
Karan Parekh,Kim van der Zande,Sarah W S Ng et al.
Karan Parekh et al.
Background and objective: Whether cabazitaxel or an androgen receptor pathway inhibitor (ARPI) is the optimal treatment option for poor-prognosis metastatic castration-resistant prostate cancer (mCRPC), progressing on doc...
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN [0.03%]
阿帕鲁胺治疗高瘤负荷转移性激素敏感性前列腺癌患者的疗效和安全性：TITAN研究亚组分析
Alejo Rodriguez-Vida,Angel Borque,Fernando Lopez-Campos et al.
Alejo Rodriguez-Vida et al.
Background and objective: A post hoc analysis of TITAN evaluated the clinical benefit of apalutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC) with hi...
Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial [0.03%]
前列腺特异性膜抗原正电子发射断层扫描/X线计算机体层成像与常规影像检查相比指导高危前列腺癌患者放射治疗的临床分期：来自THUNDER试验二期/三期结果
Fleur Kleiburg,Piet Dirix,Valérie Fonteyne et al.
Fleur Kleiburg et al.
Background and objective: In high-risk prostate cancer, the proPSMA trial showed upstaging with prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) in 14% of patients. We ...
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts [0.03%]
加拿大前列腺癌生物标志物网络和PROCURE多机构队列中局部前列腺癌患者尿苷二磷酸葡萄糖醛酸转移酶2B17胞浆表达的预后价值分析
Ashwini Uchil,Louis Lacombe,Hélène Hovington et al.
Ashwini Uchil et al.
Background and objective: Prostate cancer (PCa) is hormone dependent, with UDP-glucuronosyltransferase 2B17 (UGT2B17) playing a central role in androgen inactivation. This study aimed to evaluate whether UGT2B17 expressio...
MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses [0.03%]
microRNA作为检测小睾丸肿物恶性的液体生物标志物
Julian Chavarriaga,Carley Langleben,João Lobo et al.
Julian Chavarriaga et al.
Background and objective: Approximately 1-4% of individuals undergoing scrotal ultrasound are found with incidental small (≤2 cm) testicular masses (STMs), with the vast majority being benign (∼13-21% malignant). This s...